Financial Daily from THE HINDU group of publications
Friday, Dec 16, 2005


News
Features
Stocks
Shipping
Archives
Google

Group Sites

Corporate - Alliances & Joint Ventures


Glenmark inks pact with InvaGen for US market

Our Bureau

Mumbai , Dec. 15

GLENMARK Pharmaceuticals Ltd and the US-based InvaGen Pharmaceuticals Inc have entered into a pact for the American market. The two companies will jointly develop, file and market seven generic pharmaceutical products specifically for this market.

The product list includes a mixture of off-patent and patent-protected molecules with cumulative annual sales in the US of about $ 4.1 billion, a Glenmark communiqué said.

As per the agreement, InvaGen will develop and licence to Glenmark seven generic products. It will also undertake filing the ANDAs (Abbreviated New Drug Applications) while Glenmark will be responsible for obtaining regulatory approval in the US market, the note added.

On receiving regulatory approval, Glenmark's US subsidiary - Glenmark Pharmaceuticals Inc - will exclusively market the products while InvaGen will manufacture them. All development and regulatory costs and profits on sale in the US will be shared equally between the two companies, the note said. One ANDA has already been filed till date and three more are expected by March.

Glenmark has also signed a collaboration agreement with another Indian company, Shasun Chemicals and Drugs Ltd, for the joint development and marketing of 13 generic products in the US market. Shasun is expected to file two of its ANDAs under this agreement by March.

Meanwhile Glenmark also said that it has achieved half its target of filing a total of 12-14 ANDAs during FY 2006 on the back of in-house efforts. It is on course to meet its target by March, the company said.

More Stories on : Alliances & Joint Ventures

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Celebrity Fashions IPO price band fixed at Rs 160-180


IOC saves Rs 1,500 cr with Kandla-Bhatinda crude pipeline
ONGC board to consider interim dividend
Natco launches anti-fungal drug
Aurobindo Pharma gets USFDA nod to sell depression drug
Yellow Pages to be distributed at select petrol bunks in Coimbatore
Kirloskars cannot hike stake in Toyota Kirloskar beyond 11% — Original share buyback deal renegotiated
MoU controversy: DPE panel to study versions of ONGC, Ministry?
Nagarjuna Construction prices GDR at $ 5.11
IDMA patent awards for Aurobindo Pharma
VSP bags energy award
Learning to manage `tomorrow'
Managing with more
Finding the leader
Tata Steel to buy Thai co for $130 m
US co to buy stake in Biocon's subsidiary
Japanese firm Yanmar forays into farm implements market
Volkswagen team likely to visit Mangalore today
Glenmark inks pact with InvaGen for US market
IOC-OIL combine explores tie-up with Norway co
Torrent Pharma announces stock split, 1:1 bonus
Fresh revival plan for Dunlop to be submitted to BIFR on Jan 27
Hindustan Latex targets Rs 1,000-cr turnover
Venky's bets big on export of value-added chicken to Japan
Mankind Pharma targets Rs 1,000-cr turnover in 5 years
HPL eyes 20% sales growth
ISMT to focus on exports


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line